HOXA11-AS (HOXA11 Antisense RNA)

HOXA13, HOXD4, and HOXD8 were explored in five independent cohorts. HOX genes and their associated lncRNAs exhibit prognostic associations in patients with CRCLM and may act as biomarkers to refine clinical decision-making.

LncRNA HOXA11-AS is aberrantly overexpressed in ESCC and functions as an oncogene, driving tumor progression by enhancing proliferation, migration, invasion and suppressing apoptosis. Its association with poor prognosis identifies HOXA11-AS as a promising prognostic biomarker and potential therapeutic target for ESCC.

This scoping review highlights the diversity of EZH2-containing ceRNA axes in cancer, suggesting their potential as therapeutic targets. Further studies are needed to clarify their roles and clinical utility.

The journal retracts the article "HOXA11-AS1 promotes PD-L1-mediated immune escape and metastasis of hypopharyngeal carcinoma by facilitating PTBP1 and FOSL1 association" [...].

HOXA11-AS is a critical regulator of normal endometrial development. HOXA11-AS is elevated in endometriosis contributes to its pathophysiology. This long non-coding RNA was decreased in women undergoing endometriosis treatment with progestins. HOXA11-AS regulated several key drivers of disease and repression during treatment likely has a central role in preventing growth and invasion of endometriosis.

In addition, HOXA11-AS modulated ATG12 via sponging miR-214-3p. Overall, this research indicated that lncRNA HOXA11-AS not only stimulates cell proliferation and autophagy but also inhibits apoptosis via the miR-214-3p/ATG12 axis, thereby suggesting that lncRNA HOXA11-AS might be a new candidate for T-ALL diagnosis and therapy.

Estrogen and its related proteins have therapeutic effects in HCC and may be new potential therapeutic targets.

Moreover, HMGB3 knockdown suppressed proliferation and migration by PDAC cells. These results suggest that HOXA11-AS contributes to PDAC progression, at least in part, through regulation of IFNL and HMGB family genes and that HOXA11 AS is a potential therapeutic target in PDAC.

Our study established a concise CDG-RlncRNA signature and underscored the pivotal role of SNHG3 in ccRCC progression. It emphasizes the clinical relevance of CDG-RlncRNAs in prognostic prediction and targeted therapy, offering potential avenues for personalized intervention in ccRCC.

CA has a specific lncRNA profile, and the differentially expressed lncRNAs play regulatory roles in mRNA expression through cis-acting TFs, which provides insight into their regulatory networks. It will be useful to understand the pathogenesis of CA to provide new directions for the prevention, clinical treatment and efficacy evaluation of CA.

HOXA11-AS silencing significantly inhibited tumour development in vivo. In summary, silencing HOXA11-AS can inhibit PCa by regulating glucose metabolism and may provide a future guidance for the treatment of PCa.

We demonstrated that hypoxia/inflammation-induced upregulation of HIF-1α and C/EBPβ promoted nephroblastoma EMT by improving HOXA11-AS transcription. HOXA11-AS might be a therapy target for nephroblastoma.